SCHEMBL6166597

SCHEMBL6166597

COc1ccc2c(c1B(O)O)CCCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ENPP2 Q13822 1/20 0.36
ADRA1A P35348 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
ORAI1 Q96D31 1/20 0.35
ORAI2 Q96SN7 1/20 0.35
ORAI3 Q9BRQ5 1/20 0.35
BCL2L1 Q07817 1/20 0.35
BAD Q92934 1/20 0.35
HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167338 0.82 ALDH1A1 (0.38) KMT2AALDH1A1MAPTBCL2L1BAD
SCHEMBL4128903 0.77 CETP (0.48) CETPHTR2AHTR2CHTR2BLMNA
SCHEMBL17770807 0.76 KDM4E (0.46) CETPHTR2AHTR2CHTR2BMEN1
SCHEMBL21872026 0.74 HTR2A (0.42) CETPHTR2AHTR2CHTR2BLMNA
SCHEMBL8960045 0.74 KDM4E (0.49) HTR2AHTR2CHTR2BLMNAMEN1
SCHEMBL5768620 0.74 MEN1 (0.38) LMNASMN1; SMN2MEN1KMT2AENPP2
SCHEMBL6168691 0.73 HTR2A (0.41) CETPHTR2AHTR2CHTR2BLMNA
SCHEMBL22103244 0.73 HTR2A (0.41) CETPHTR2AHTR2CHTR2BLMNA
SCHEMBL19432994 0.73 HTR2A (0.41) CETPHTR2AHTR2CHTR2BLMNA
SCHEMBL6959755 0.73 CETP (0.44) CETPHTR2AHTR2CHTR2BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910592-B2 CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2011-03-22 US disclosed
US-20090042892-A1 Cetp Inhibitors MERCK SHARP & DOHME LLC 2009-02-12 US disclosed
US-6964965-B2 Substituted pyrazine derivatives PHARMACIA & UPJOHN (US) 2005-11-15 US disclosed
EP-1499599-A1 SUBSTITUTED PYRAZINE DERIVATIVES Pharmacia & Upjohn Company LLC (US) 2005-01-26 EP disclosed
US-20040053941-A1 Substituted pyrazine derivatives PHARMACIA & UPJOHN COMPANY 2004-03-18 US disclosed
WO-2003091225-A1 SUBSTITUTED PYRAZINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042892-A1 Cetp Inhibitors CETP, APOB, MTTP CETP 1/4885HTR2A 4433/4885HTR2C 4486/4885
US-20040053941-A1 Substituted pyrazine derivatives CRHR1, CRHR2, CRH CETP 3924/4885HTR2A 32/4885HTR2C 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.